PGEN — Precigen Cashflow Statement
0.000.00%
- $160.70m
- $91.00m
- $3.93m
Annual cashflow statement for Precigen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -171 | -92.2 | 28.3 | -95.9 | -126 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 96.8 | 23.6 | -81.3 | 19.4 | 52.7 |
Discontinued Operations | |||||
Unusual Items | |||||
Purchased R&D | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -20.7 | -0.804 | -22.7 | 3.4 | 2.66 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -77 | -55.8 | -65 | -66.9 | -68.2 |
Capital Expenditures | -7.53 | -7.25 | -4.92 | -1.54 | -8.58 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 35.3 | -67.3 | 231 | -1.55 | -12.1 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 27.8 | -74.5 | 226 | -3.09 | -20.7 |
Financing Cash Flow Items | — | — | -0.588 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 32.7 | 121 | -155 | 29.6 | 111 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -16.2 | -8.91 | 5.25 | -40.7 | 21.7 |